Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Interpreting and subtyping type 2 diabetes (T2D) is challenging yet essential for achieving fine-grained pathophysiological insights and precise clinical stratification. Previous studies have primarily relied on a small number of pre-selected risk factors and biomarkers, neglecting the integration of multimodality data (e.g., phenotypic and genetic features) for more comprehensive analyses. In this study, we select a cohort of 42,256 participants from the National Institutes of Health's All of Us Research Program, where our hypergraph framework achieves an AUROC of 89.64% on predicting T2D when integrating phenotypic and genetic features. The proposed pipeline performs subtyping by clustering clinical concepts, genetic variants, and individuals in an end-to-end manner. Further analysis using genetic risk scores reveals distinct genetic profiles between T2D subtypes and highlights the potential applications of our solution in precision medicine.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399298PMC
http://dx.doi.org/10.3233/SHTI251002DOI Listing

Publication Analysis

Top Keywords

type diabetes
8
phenotypic genetic
8
genetic features
8
genetic
5
diabetes subtyping
4
subtyping phenotype
4
phenotype genotype
4
genotype co-learning
4
co-learning interpreting
4
interpreting subtyping
4

Similar Publications

Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.

Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.

View Article and Find Full Text PDF

Indigenous Peoples experience the highest age-adjusted prevalence of type 2 diabetes of any racial group in the U.S. Though the management of type 2 diabetes requires regular healthcare visits, North American Indigenous individuals with diabetes do not always utilize the healthcare available to them, and this lack of utilization may lead to poor health outcomes over time.

View Article and Find Full Text PDF

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.

View Article and Find Full Text PDF

Introduction: This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA).

Methods: The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis.

View Article and Find Full Text PDF

Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.

View Article and Find Full Text PDF